Drug Trial Radar · NCT03997968
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Dec 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
169
Actual
Start
Oct 9, 2019
Primary completion
Nov 30, 2024
Study completion Dec 20, 2024
Sponsor
- Lead sponsor
- Cyteir Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.
Conditions
- Malignancy
- Non-hodgkin Lymphoma
- Multiple Myeloma
- Breast Cancer
- Ovarian Cancer
- Soft Tissue Sarcoma
- Head and Neck Cancer
- DLBCL
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Pancreatic Cancer
- CLL
- Small Cell Lung Cancer
- Squamous Cell Carcinoma of Head and Neck
- Triple Negative Breast Cancer
Interventions
CYT-0851Drug
Part A and B: Daily oral doses of CYT-0851 for 28 day cycles
CYT-0851 in combination with gemcitabineDrug
Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine
CYT-0851 in combination with capecitabineDrug
Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine
CYT-0851 in combination with rituximab and bendamustineDrug
Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab and bendamustine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Incidence of dose limiting toxicityTime frame: 28 Days
- Part B: Objective response rateTime frame: 24 Weeks
- Part C: Incidence of dose limiting toxicityTime frame: 28 Days
- Part D: Incidence of dose limiting toxicityTime frame: 28 Days
- Part E: Incidence of dose limiting toxicityTime frame: 21 Days
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
Stanford Comprehensive Cancer Center
Stanford, California
Sarah Cannon Research Institute at HealthONE
Denver, Colorado
Florida Cancer Specialists and Research Institute
Sarasota, Florida
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
John Theurer Cancer Center at HUMC
Hackensack, New Jersey
NYU Langone Health
New York, New York
Oklahoma University-Stephenson Cancer Center
Oklahoma City, Oklahoma
Thomas Jefferson University, Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
University of Washington Seattle Cancer Center
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.